{
  "ticker": "JNJ",
  "target_date": "2025-01-15",
  "actual_date": "2025-01-15",
  "collected_at": "2025-12-08T11:16:46.177019",
  "price": {
    "open": 140.99,
    "high": 141.71,
    "low": 139.98,
    "close": 140.6641845703125,
    "volume": 7434600,
    "change_1d_pct": 0.15,
    "change_7d_pct": 0.54,
    "change_30d_pct": -6.48
  },
  "technicals": {
    "rsi_14": 49.02,
    "sma_20": 140.18,
    "sma_50": 144.94,
    "macd": -1.508,
    "macd_signal": -1.914,
    "macd_histogram": 0.407,
    "bb_upper": 142.42,
    "bb_lower": 137.93,
    "price_vs_sma20_pct": 0.35,
    "price_vs_sma50_pct": -2.95,
    "volume_ratio": 0.9
  },
  "fundamentals": {
    "market_cap": 488894169088,
    "pe_ratio": 19.586874,
    "forward_pe": 19.143394,
    "price_to_book": 6.1589828,
    "price_to_sales": 5.3054748,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.24
  },
  "macro": {
    "spy": {
      "price": 587.63,
      "change_1d_pct": 1.82,
      "change_7d_pct": -0.43
    },
    "vix": {
      "level": 16.12,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.65
    },
    "dollar_index": {
      "level": 109.09
    },
    "gold": {
      "price": 2712.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Buy 3 'Safer' Dividend Kings Of 25 From 53\u00a0For January",
      "source": "SeekingAlpha",
      "datetime": 1736944797,
      "summary": "53 Dividend Kings offer steady growth across sectors. See why MO, UBSI, and HRL are top picks for January with yields greater than their single-share prices.",
      "url": "https://finnhub.io/api/news?id=1a4d5878f76b071b3de965ed29cf79dc044e68a10ad7d2c3e5c575f591fb07e2"
    },
    {
      "headline": "Johnson & Johnson: FDA to review TAR-200 dossier",
      "source": "Finnhub",
      "datetime": 1736937316,
      "summary": "Johnson & Johnson announced on Wednesday that the U.S. Food and Drug Administration had agreed to review its application for registration of TAR-200, an experimental treatment for bladder cancer.The...",
      "url": "https://finnhub.io/api/news?id=3c56dc18b10597fba8292a4a295d898618caff23b614e429715e2c9017b67d3a"
    },
    {
      "headline": "J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer",
      "source": "Finnhub",
      "datetime": 1736930496,
      "summary": "By Colin Kellaher Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with...",
      "url": "https://finnhub.io/api/news?id=da08fe5ab36bca8e7af09598c567873ec14f50cd95d895d6e46d1ba6b15577c7"
    },
    {
      "headline": "New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer",
      "source": "Finnhub",
      "datetime": 1736928073,
      "summary": "Application accepted for U.S. FDA Real-Time Oncology Review based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1RARITAN, N.J., Jan. 15, 2025...",
      "url": "https://finnhub.io/api/news?id=6075170b5edd2d10f3795ec305800a1ed5af5231859db546babeaf8c05207360"
    },
    {
      "headline": "ClearBridge Value Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1736925600,
      "summary": "Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.",
      "url": "https://finnhub.io/api/news?id=16104d7a68c2939ee98b902963633ee224985f62212a98b4fd4a0b33be489f73"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}